New cancer drug enters first human trials for advanced tumors

NCT ID NCT06724016

Recruiting now Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

Summary

This is the first study in people testing a new cancer drug called HM16390. Researchers want to find the safest and most effective dose, both by itself and combined with an existing immunotherapy drug (pembrolizumab). The trial will enroll 292 adults with advanced or metastatic solid tumors who have not benefited from standard treatments, to see if the drug can help control their cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asan Medical Center
ACTIVE_NOT_RECRUITING

Seoul, 05505, South Korea
Karmanos Cancer Institute
NOT_YET_RECRUITING

Detroit, Michigan, 48201, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Bundang Hospital
RECRUITING

Seongnam-si, Gyeonggi-do, 13620, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Severance Hospital
RECRUITING

Seoul, 03722, South Korea

Conditions

Explore the condition pages connected to this study.

ADVANCED OR METASTATIC SOLID TUMORS